Suomen sivusto, jossa voit ostaa halvalla ja laadukas Viagra http://osta-apteekki.com/ toimitus kaikkialle maailmaan.

Yritti äskettäin viagra, se toimii erittäin tehokkaasti)) Ostaa Internetin kautta täällä levitra Myös ostaa levitra oikeudenkäynti, vaikutus on silmiinpistävää.

Dectomax.co.nz

SAFETY DATA SHEET
Pfizer New Zealand Limited
14 Normanby Road, Mt Eden, Auckland

Section 1: IDENTIFICATION OF THE SUBSTANCE AND SUPPLIER
Trade Name:
DECTOMAX®
ACVM Registration No.:
Classification:
Recommended Use:
An injectable endectocide for the treatment and control of doramectin-sensitive gastrointestinal roundworms (including inhibited larvae of Ostertagia ostertagi), lungworms, sucking lice and mange of cattle and internal and external parasites of sheep and pigs. Company Details:
Address:
Level 3, Pfizer House 14 Normanby Road Mt Eden Auckland 1024 NEW ZEALAND Telephone No.:
Emergency Telephone No.:
National Poisons Centre: 0800 POISON (0800 764 766) Emergency Services: Date of Preparation:
Section 2: HAZARDS IDENTIFICATION

Hazard Classification:

6.1E, 6.8B, 6.8C, 6.9B, 9.1A, 9.2C, 9.4A Priority Identifier(s):
HARMFUL – KEEP OUT OF REACH OF CHILDREN DANGEROUS TO THE ENVIRONMENT Secondary Identifier(s):
May be harmful if swallowed, inhaled or absorbed through the skin. Suspected of damaging fertility or the unborn child from repeated oral May cause harm to breast-fed children from repeated oral exposure. May cause target organ damage from repeated oral exposure to high Very toxic to aquatic organisms. Avoid contamination of any water Very toxic to terrestrial invertebrates. Section 3: COMPOSITION / INFORMATION ON INGREDIENTS
MIXTURE:
Chemical Identity of Ingredients
Ingredient CAS
Concentration
Other ingredients determined not to be hazardous. This is a commercial product whose exact ratio of components may vary. Trace quantities of impurities are also likely. Section 4: FIRST AID MEASURES
Necessary First Aid
For advice contact the National Poisons Centre at 0800 POISON (0800 764
Measures:
766) or a doctor immediately. If the patient is not breathing begin artificial
respiration and seek medical advice immediately. Never give fluids or induce
vomiting if a patient is unconscious or convulsing, regardless of injury.
Self-Injection: Immediate medical advice should be sought on the
management of all instances of accidental self-injection,
particularly those near a joint or associated with bruising. Allow
the wound to bleed freely and avoid squeezing the injection site
to avoid spread of the product. Clean the wound thoroughly
with soap and water, and then keep it clean and dry.

Ingestion:
DO NOT induce vomiting. If the patient is conscious wash mouth out with water. Do not give anything by mouth to an unconscious person. Seek medical advice immediately.
Eye Contact:
Flush the eye(s) out with running water for at least 15 minutes. Removal of contact lenses should be done with caution within 5 minutes of exposure. If symptoms develop seek medical advice immediately.
Skin Contact: Remove any contaminated clothing and wash the affected area
immediately with soap and water. If symptoms develop seek medical advice immediately.
Inhalation:
Move the patient to fresh air. If symptoms develop seek medical advice immediately. Poisoning Symptoms:
Signs and symptoms of exposure include respiratory depression, weakness, tremors and ataxia. Workplace Facilities:
No specific facilities required. Standard emergency equipment must be available. Hygiene Practices:
Avoid self-injection, ingestion, contact with skin and eyes, and inhalation of
dusts, mists or vapours. Do not eat, drink or smoke while using this product.
Wash hands and exposed skin before eating, drinking or smoking and after
work. Wash any protective clothing after use.

Notes for Medical
This product contains sesame oil as a vehicle. Accidental self-injection may lead Personnel:
to an inflammatory response and deep injections, particularly those near a joint or associated with bruising should be treated medically or surgical y. Section 5: FIRE-FIGHTING MEASURES
Type of hazard:
This product is not flammable, however, irritating and possibly toxic gases may be generated by thermal decomposition or combustion. Fire Hazard Properties:
Heat may cause violent rupture of containers. Regulatory Requirements:
Extinguishing Media and
Use dry chemical, foam, carbon dioxide or water to extinguish fires Methods:

Hazchem Code:

Recommended Protective
Wear approved positive pressure, self-contained breathing apparatus and Clothing:
full protective turn-out gear during large-scale fire-fighting operations.
Pfizer New Zealand Limited
Section 6: ACCIDENTAL RELEASE MEASURES
Personal Precautions:
Personnel involved in clean-up should wear appropriate personal protective equipment to minimise exposure. This may include eye protection, chemically resistant gloves, boots and overalls. Environmental Precautions:
Prevent material from entering surface water drains or waterways. If a significant quantity of material enters drains, advise emergency services. Procedure for Spills:
1. Non-essential personnel should be evacuated from the affected area. 2. Stop leak and contain the source of spill if it is safe to do so. Reposition any leaking containers to minimise further leakage. 3. Absorb the spill with an absorbent material (e.g. sand). 4. Collect the spil ed material into labelled containers for disposal, 5. Decontaminate the spill area thoroughly with detergent and water, Procedure for Disposal:
Contaminated material must be disposed of at an approved landfill or other approved facility in accordance with local, regional and national requirements. Avoid contamination of any water supply with product or empty container. Section 7: HANDLING AND STORAGE
HANDLING:
Precautions for Safe Handling:
No special technical protective measures required. No special handling advice required. Regulatory Requirements:
Handling Practices:
Avoid self-injection, ingestion, contact with skin and eyes, and inhalation
of dusts, mists or vapours. Do not eat, drink or smoke while using this
product. Wash hands and exposed skin before eating, drinking or
smoking and after work.

Approved Handlers:
Approved handlers are not required for this product. STORAGE:
Conditions for Safe Storage:
Store below 30°C (Room Temperature). Protect from light. Store in a well ventilated area in the original container, tightly closed, away from foodstuffs. Store Site Requirements:
A requirement for an emergency management plan, secondary containment and signage is applicable when quantities of ≥ 100 L are stored. Packaging:
Packaging Schedule 3 (UN Packing Group III) for quantities > 5 L (Hazardous Substances Packaging Regulations 2001). Section 8: EXPOSURE CONTROL / PERSONAL PROTECTION
ALWAYS READ AND FOLLOW THE LABEL INSTRUCTIONS AND WARNINGS
WORKPLACE EXPOSURE GUIDELINES:
Workplace Exposure
A time weighted average (TWA) concentration for an 8-hour day and a Standards:
5-day week has not been established by NOHSC Australia for any of the major ingredients in this product. There is a blanket limit of 10 mg/m3 for dusts or mists when limits have not otherwise been established. Application in the Workplace:
The nature of this product makes it unlikely that this level will be approached during normal handling. Exposure Standards Outside
the Workplace:
Engineering Controls:

Engineering controls should be used as the primary means to control exposures. Use process enclosures, local exhaust ventilation, or other engineering controls to maintain airborne levels below recommended exposure limits. Personal Protection:
The following instructions are for those coming into frequent and / or lengthy contact with this product. For occasional handling employ precautions suitable for the conditions under which the product is being handled. Hands: Impervious gloves are recommended if skin contact is possible and for bulk processing operations. It is always prudent to utilise protective eyewear. When prolonged or frequently repeated contact could occur, utilise chemically protective clothing. Selection of specific items such as a face shield, gloves, boots, or overalls will depend on the situation. Respiratory: Respiratory protection is not normally required; however, if necessary utilise an air-purifying respirator that complies with NZ standards. General Hygiene:
Change work clothes regularly. Avoid self-injection, ingestion, contact
with skin and eyes, and inhalation of dusts, mists or vapours. Do not eat,
drink or smoke while handling this product. Wash hands and exposed
skin before eating, drinking or smoking and after work. Wash any
protective clothing after use.

Section 9: PHYSICAL AND CHEMICAL PROPERTIES

Appearance:

Specific Gravity / Density:
Freezing / Melting Point:
Boiling Point:
No data available. Expected to decompose before boiling Solubility in Water:
Flashpoint:
Oxidising Properties:
Not applicable. This product is not an oxidiser Corrosive Properties:
Not applicable. This product is not corrosive Vapour Pressure:
Less than 7 x 10–7 torr at 20°C (doramectin) Section 10: STABILITY & REACTIVITY
Stability of the Substance:
This product is stable under normal conditions of use. Conditions to Avoid:
Store as recommended. No specific conditions to avoid. Material to Avoid:
Hazardous Decomposition
Thermal and photolytic decomposition of doramectin gives rise to a Products:
number of compounds from oxidation of radicals. None of these degradation by-products are considered more toxic than the parent compound. Hazardous Polymerisation:
This product is unlikely to spontaneously polymerise. Specific Data:
Section 11: TOXICOLOGICAL INFORMATION
HSNO CLASSIFICATIONS:
May be harmful if swallowed, inhaled or absorbed through the skin. Suspected of damaging fertility or the unborn child from repeated oral exposure. May cause harm to breast-fed children from repeated oral exposure. May cause target organ damage from repeated oral exposure to high doses. ACUTE EFFECTS:
Primary route of exposure is accidental self-injection or by skin exposure from breakage or leakage. Should self-injection occur, it is most doubtful that the consequences would be life-threatening. While there is no data on human exposure to the compound, it is closely structurally and toxicologically related to ivermectin which has been extensively administered to humans for filarial disease in Africa for a number of years. In addition, doramectin has been shown to be almost identical in behaviour to mammalian toxicology assessment systems and in terms of acute toxicity it has been shown to be even safer than ivermectin. The formulation constituents are non-toxic oils. Therefore, the nature and use of the product makes it unlikely that any ill effects will be sustained while using the product. Self-Injection:
Local injection site reactions in humans may occur from accidental self-injection through the skin. Ingestion:
Due to the method of application, this should not occur however data suggests that the product should be considered as slightly toxic by ingestion. Doramectin:  Rat (M) Oral LD50 1000-2000 mg/kg (aqueous suspension)  Rat (F) Oral LD50 500-1000 mg/kg (aqueous suspension)  Rat(M) Oral LD50 50-100 mg/kg (in sesame oil)  Rat (F) Oral LD50 100-200 mg/kg (in sesame oil) Eye Contact:
Data suggests that this product should be classified as a minimal eye irritant. Doramectin: Skin Contact:
Data suggests that the product presents minimal hazard via skin contact. Doramectin: Inhalation:
There is no data available relating to inhalation however the mode of use of the product would make this highly unlikely.
Pfizer New Zealand Limited
CHRONIC / LONG-TERM EFFECTS:
Subchronic Effects:
Doramectin was tested in both rats and dogs. In a 3-month rat study, the only treatment related effect noted was an increase in liver weight. In dogs a 1-month study resulted in mydriasis, decreased food consumption and decreased body weight. Animals receiving the high dose (4 mg/kg/day) also exhibited tremors, salivation, ataxia, and emesis. A 3-month study in dogs produced only dose-dependent mydriasis. Carcinogenicity:
No carcinogenic data available. However, the carcinogenic potential of a structurally related avermectin, abamectin, has been investigated in rodents. No evidence of carcinogenicity was seen in these studies. None of the components of this formulation are listed as a carcinogen by IARC, NTP or OSHA. Mutagenicity:
No evidence of mutagenicity was observed for doramectin when tested in vitro and in vivo in the following assays: the Ames test, the mouse lymphoma assay, and the unscheduled DNA synthesis (UDS) assay. At Increased Risk
This material has been shown in rats to be excreted in milk and, as a result, to from Exposure:
cause toxicity in young pups; nursing mothers should exercise caution regarding Section 12: ECOTOXICITY INFORMATION
HSNO CLASSIFICATIONS:
Very toxic to aquatic organisms. Avoid contamination of any water supply with product or empty container. Very toxic to terrestrial invertebrates. The environmental characteristics of this material have not been fully evaluated. Avoid contamination of any water supply with product or empty container. ECOTOXIC EFFECTS:
Aquatic Toxicity:
Toxicity to Birds:

Toxicity to Soil Dwelling Organisms:
No information available.

Acute Toxicity to Bees:

ENVIRONMENTAL FATE:
In the environment, the active ingredient in this formulation is expected to bind tightly to soil or sediment and readily desorb. It is unlikely to reach groundwater and is also biodegradable by soil microflora. Harmful effects to aquatic organisms could occur.
Pfizer New Zealand Limited
Section 13: DISPOSAL CONSIDERATIONS
Product Disposal:
Preferably dispose of product by use in accordance with label directions. Otherwise dispose of product at an approved landfill, or other approved facility in accordance with local, regional and national regulations. Avoid contamination of any water supply with product. Container Disposal: Dispose of empty containers by wrapping in paper and putting in garbage for
disposal at an approved landfill, or other approved facility in accordance with local, regional and national regulations. Avoid contamination of any water supply with product. Used needles and syringes should immediately be placed in a designated and appropriately labelled “sharps” container. Section 14: TRANSPORT INFORMATION
DANGEROUS GOODS CLASSIFICATION:
Packing Group:
Proper Shipping Name:
Environmentally Hazardous Substance, Liquid or N.O.S Section 15: REGULATORY INFORMATION

HSNO Approval No.:

HSNO Controls:
See http://www.ermanz.govt.nz/search/registers.html for controls. ACVM Registration No.: A006199
ACVM Controls:
See http://www.nzfsa.govt.nz/acvm/ for registration conditions. Section 16: OTHER INFORMATION

Note:
This product is a veterinary medicine and must therefore be used in accordance with the container label directions. A
comprehensive package of toxicological and environmental data for the active ingredients of this product has been submitted to the
Government health and environment authorities and has been evaluated by expert toxicologists and environmental scientists.

CONTACT POINT: Pfizer Animal Health:
National Poisons Centre:
Emergency Services: Dial
This Safety Data Sheet summarises our best knowledge of the health and safety hazard information of the product and how to safely handle and use the product in the workplace. Each user should read this SDS and consider the information in the context of how the product will be handled and used in the workplace including in conjunction with other products. PLEASE READ ALL LABELS CAREFULLY BEFORE USING PRODUCT.
If clarification of further information is needed to ensure that an appropriate risk assessment can be made, the user should contact this company.

Source: http://www.dectomax.co.nz/media/1124/pfizer%20sds%20-%20dectomax%20(22%20feb%202010).pdf

Microsoft word - ex for s-block.doc

(Ex. from Past Exam Questions) 7. Sketch the trends for the properties mentioned below, and account for the trend in 1. Describe the interaction among the entities in each of the following species: (i) zinc (i) melting point of the alkali metals, Li, Na and K (ii) boiling point of the Period 3 elements, Na, Mg and Al (iii) solubility in water of the Group II sulphates(VI), MgSO2. The lat

43949-acr 2011 p2228 vf.indd

Initial Combination Therapy With Adalimumab Plus Methotrexate Leads to Better Long-term Outcomes in Patients With Advanced Rheumatoid Arthritis: Analysis of the Final 10-Year Results of an Open-label Extension of a Phase 3 Trial Edward C Keystone1, Désirée van der Heijde2, Michael E Weinblatt3, Neelufar Mozaffarian4, Benoît Guérette4, Hartmut Kupper5, Shufang Liu4, Arthur Kavanaugh6 1Uni

Copyright © 2010-2014 Medical Pdf Articles